|

Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple Sclerosis

RECRUITINGSponsored by Afyonkarahisar Health Sciences University
Actively Recruiting
SponsorAfyonkarahisar Health Sciences University
Started2026-03-20
Est. completion2026-07-25
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted

Summary

This cross-sectional observational study aims to investigate the relationship between obstacle crossing performance under single-task and dual-task conditions and the levels of fatigue and disability in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS). Walking performance will be assessed under standard walking and obstacle crossing conditions with and without a concurrent cognitive task. The study will examine how increased task complexity affects walking performance and its association with fatigue, disability, cognition, and functional mobility.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age between 18 and 65 years.
* Diagnosis of Multiple Sclerosis according to the 2017 McDonald criteria.
* Diagnosis of Relapsing-Remitting Multiple Sclerosis.
* Expanded Disability Status Scale (EDSS) score between 0 and 6.
* Clinically stable disease during the previous 6 months.
* Montreal Cognitive Assessment (MoCA) score of 26 or higher.
* Able to speak and understand Turkish.
* Able to provide written informed consent.

Exclusion Criteria:

* Multiple sclerosis relapse within the previous month.
* Physician-diagnosed psychiatric disorder.
* Neurological, orthopedic, cardiac, or pulmonary disease other than Multiple Sclerosis that could interfere with study assessments.
* Montreal Cognitive Assessment (MoCA) score below 26.

Conditions1

Multiple Sclerosis

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.